title: Survival and safety of treatment with infliximab in the elderly population.
authors.forename: H
authors.initials: H
authors.lastname: Chevillotte-Maillard
authors.forename: P
authors.initials: P
authors.lastname: Ornetti
authors.forename: R
authors.initials: R
authors.lastname: Mistrih
authors.forename: C
authors.initials: C
authors.lastname: Sidot
authors.forename: J
authors.initials: J
authors.lastname: Dupuis
authors.forename: J-A
authors.initials: JA
authors.lastname: Dellas
authors.forename: C
authors.initials: C
authors.lastname: Tavernier
authors.forename: J F
authors.initials: JF
authors.lastname: Maillefert
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000009:adverse effects; D047889:Receptors, Tumor Necrosis Factor, Type II; D013167:Spondylitis, Ankylosing / Q000188:drug therapy; D053319:Tumor Necrosis Factor Decoy Receptors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D009363:Neoplasm Proteins; D047889:Receptors, Tumor Necrosis Factor, Type II; D053319:Tumor Necrosis Factor Decoy Receptors; D000069285:Infliximab